Physician profile
John P Deveikis
NPI 1124061775
$64,520.57
in general payments reported to CMS, 2019-2025
8 companies · $13K in 2025
The $13K reported for 2025 was more than what 97% of Diagnostic Radiology providers received nationally (typical 2025 total: $112).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $215 · 2021: $42.10 · 2022: $22K · 2023: $9,437 · 2024: $20K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $37K · Travel and Lodging: $3,225 · Food and Beverage: $1,755.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $36,857.10 |
| Travel and Lodging | $3,224.55 |
| Food and Beverage | $1,754.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scientia Vascular | $63,855.21 | 2022-2025 | |
| Stryker Corporation | $201.93 | 2019 | |
| Depuy Synthes Sales INC. | $152.15 | 2022-2025 | Embotrap, Prowler |
| Rapid Medical Ltd | $131.50 | 2024 | Tigertriever 17 Revascularization Device, Comaneci 17 |
| Balt USA, LLC | $89.33 | 2021-2022 | |
| Imperative Care, INC | $54.94 | 2022 | |
| Medtronic, INC. | $22.63 | 2025 | Pipeline |
| Ge Healthcare | $12.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,860,052.48 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Deveikis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.